This, coupled with the absence of a group-associated effect, suggests that CNS rather than systemic immune cells likely contribute to the CHI3L2 elevations reported in the CSF of ALS patients. The gene discussed is CHI3L2; the disease is amyotrophic lateral sclerosis.